{"id":3530,"date":"2015-11-25T20:33:35","date_gmt":"2015-11-25T20:33:35","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3530"},"modified":"2015-11-25T20:33:35","modified_gmt":"2015-11-25T20:33:35","slug":"therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","title":{"rendered":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab"},"content":{"rendered":"

AMB 2015, 49, 85 Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab Fazit: In der FUTURE-2-Studie besserte der Anti-Interleukin-17A-Antik\u00f6rper Secukinumab in den h\u00f6heren hier verwendeten Dosierungen deutlich die Symptome bei Patienten mit aktiver Psoriasisarthritis. Allerdings waren in dieser Studie auch Patienten eingeschlossen worden, die bereits ein Glukokortikosteroid bzw. Methotrexat einnahmen.\u00a0 Bitte abonnieren oder Kennlernartikel anfordern –> […]<\/p>\n","protected":false},"excerpt":{"rendered":"

AMB 2015, 49, 85 Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab Fazit: In der FUTURE-2-Studie besserte der Anti-Interleukin-17A-Antik\u00f6rper Secukinumab in den h\u00f6heren hier verwendeten Dosierungen deutlich die Symptome bei Patienten mit aktiver Psoriasisarthritis. Allerdings waren in dieser Studie auch Patienten eingeschlossen worden, die bereits ein Glukokortikosteroid bzw. Methotrexat einnahmen.\u00a0 Bitte abonnieren oder Kennlernartikel anfordern –> […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[2199,212,2198,2197,2153],"class_list":["post-3530","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-future-2-studie","tag-psoriasis","tag-psoriasisarthritis","tag-schuppenflechte","tag-secukinumab"],"yoast_head":"\nTherapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab<\/title>\n<meta name=\"description\" content=\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\" \/>\n<meta property=\"og:description\" content=\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-25T20:33:35+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\",\"datePublished\":\"2015-11-25T20:33:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\"},\"wordCount\":169,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"FUTURE-2-Studie\",\"Psoriasis\",\"Psoriasisarthritis\",\"Schuppenflechte\",\"Secukinumab\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\",\"name\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2015-11-25T20:33:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","description":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","og_locale":"de_DE","og_type":"article","og_title":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","og_description":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2015-11-25T20:33:35+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","datePublished":"2015-11-25T20:33:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/"},"wordCount":169,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["FUTURE-2-Studie","Psoriasis","Psoriasisarthritis","Schuppenflechte","Secukinumab"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/","name":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2015-11-25T20:33:35+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-psoriasisarthritis-humaner-monoklonaler-anti-interleukin-17a-antikoerper-secukinumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Therapie der Psoriasisarthritis: Humaner monoklonaler Anti-Interleukin-17A-Antik\u00f6rper Secukinumab"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3530"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3530\/revisions"}],"predecessor-version":[{"id":3531,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3530\/revisions\/3531"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}